A 600 mg of fixed‐dose linezolid in renally impaired patients versus 15 mg/kg intermittent dose‐optimized vancomycin in renally non‐impaired patients: A single centre retrospective analysis for adult patients with hospital‐acquired pneumonia due to methicillin‐resistant Staphylococcus aureus

• Published in: Tropical medicine & international health 2023-04, Vol.28 (4), p.315-323
• Main Authors: Wang, Mengqin, Liu, Xiao, Tian, Zhaoxing
• Format: Article
• Language: English
• Subjects: Adult; Anti-Bacterial Agents; Creatinine - therapeutic use; Cross Infection - chemically induced; Cross Infection - drug therapy; Healthcare-Associated Pneumonia - drug therapy; Hospitals; hospital‐acquired pneumonia; Humans; linezolid; Linezolid - therapeutic use; Methicillin-Resistant Staphylococcus aureus; nephrotoxicity; Pneumonia, Staphylococcal - chemically induced; Pneumonia, Staphylococcal - drug therapy; Renal Insufficiency - chemically induced; Renal Insufficiency - complications; Retrospective Studies; Treatment Outcome; vancomycin; Vancomycin - adverse effects; Vancomycin - therapeutic use
• ISSN: 1360-2276; 1365-3156
• DOI: 10.1111/tmi.13866

Objectives Both linezolid and vancomycin are approved by USFDA and IDSA guidelines for the management of nosocomial pneumonia due to methicillin‐resistant Staphylococcus aureus (MRSA) in clinical practice. Baseline creatinine clearance is the criterion for prescribing vancomycin or linezolid for hospital‐acquired pneumonia in our institution. However, patients with renal function impairment are far more difficult to manage in intensive care. Thus, the objectives of the study were to compare the clinical efficacy and safety of 600 mg of fixed‐dose linezolid with intermittent dose‐optimised vancomycin in hospital‐acquired pneumonia due to MRSA and to evaluate parameters of clinical cure. Methods Analysis of a review of patients' charts. Patients with creatinine clearance